Et al Phillip Frost MD - 09 Nov 2023 Form 4 Insider Report for OPKO HEALTH, INC. (OPK)

Role: CEO & Chairman, Director, 10%+ Owner
Signature: Phillip Frost, M.D., Individually and as Trustee
Issuer symbol: OPK
Transactions as of: 09 Nov 2023
Net transactions value: +$1,266,933
Form type: 4
Filing time: 13 Nov 2023, 08:23:18 UTC
Previous filing: 21 Sep 2023
Next filing: 08 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OPK	Common Stock	Purchase	$12,778	+10,101	+0.01%	$1.26	200,966,795	09 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$71,373	+56,199	+0.03%	$1.27	201,022,994	09 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$786	+618	+0%	$1.27	201,023,612	09 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$118,982	+93,319	+0.05%	$1.28	201,116,931	09 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$191,697	+149,763	+0.07%	$1.28	201,266,694	09 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$15,771	+12,273	+0.01%	$1.28	201,278,967	09 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$80,599	+62,480	+0.03%	$1.29	201,341,447	09 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$86,955	+67,147	+0.03%	$1.30	201,408,594	09 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$62,530	+48,100	+0.02%	$1.30	201,456,694	09 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$2,323	+1,900	+0%	$1.22	201,458,594	10 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$107,526	+87,776	+0.04%	$1.22	201,546,370	10 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$61,750	+50,000	+0.02%	$1.24	201,596,370	10 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$6,602	+5,324	+0%	$1.24	201,601,694	10 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$23,745	+19,072	+0.01%	$1.24	201,620,766	10 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$61,851	+49,481	+0.02%	$1.25	201,670,247	10 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$626	+500	+0%	$1.25	201,670,747	10 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$49,199	+39,202	+0.02%	$1.26	201,709,949	10 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$174,977	+138,871	+0.07%	$1.26	201,848,820	10 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$505	+400	+0%	$1.26	201,849,220	10 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$30,740	+24,300	+0.01%	$1.26	201,873,520	10 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$5,704	+4,500	+0%	$1.27	201,878,020	10 Nov 2023	See Footnote	F1
transaction	OPK	Common Stock	Purchase	$99,916	+78,674	+0.04%	$1.27	201,956,694	10 Nov 2023	See Footnote	F1
holding	OPK	Common Stock						3,068,951	09 Nov 2023	Direct
holding	OPK	Common Stock						30,127,177	09 Nov 2023	See Footnote	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2	These securities are held by Frost Nevada Investments Trust, of which the Reporting Person is the trustee and Frost-Nevada, L.P. is the sole and exclusive beneficiary. The Reporting Person is one of seven limited partners of Frost-Nevada, L.P. and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Content

The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

These securities are held by Frost Nevada Investments Trust, of which the Reporting Person is the trustee and Frost-Nevada, L.P. is the sole and exclusive beneficiary. The Reporting Person is one of seven limited partners of Frost-Nevada, L.P. and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.